After adjusting for variables including painless endoscopic therapy, endoscopic therapy frequency, lymphocyte, Hb, AST, varices status, spleen thickness, ascites grade and shock, the risk of rebleeding in patients with endoscopic primary prophylaxis was decreased by 0.773 times (OR = 0.227, 95%CI: 0.139–0.372, P < 0.001) (Table 3). Here, GSTM1 is linked to varicose disease.